Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

crisaborole ointment

A topical ointment formulation composed of crisaborole, a boron-containing phosphodiesterase 4 (PDE4) inhibitor, with potential immunomodulating activity. Upon topical administration of the crisaborole ointment to the affected area(s), crisaborole targets, binds to and inhibits PDE4, which increases intracellular cyclic adenosine monophosphate (cAMP) levels. This decreases inflammation in the skin. PDE4 inhibition may reduce cetuximab-related skin toxicity and atopic dermatitis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Eucrisa
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search